Betz Stephen F. 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Jul 12, 2024
Insider Transaction Report
Form 4
Betz Stephen F.
Chief Scientific Officer
Transactions
- Sale
Common Stock
2024-07-10$48.55/sh−3,000$145,650→ 78,611 total
Footnotes (3)
- [F1]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $48.55 per share. The range of sales prices on the transaction date was $48.63 to $48.46 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- [F3]Includes 968 shares acquired under the Issuer's Employee Stock Purchase Plan.